News and Trends 25 Jul 2023 Can the microbiome help the fight against infections? Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Roche and Alnylam to work on RNAi therapeutic to treat hypertension Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […] July 25, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Crescendo Biologics raises $32M and expands cancer trial Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […] July 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 CatalYm shows importance of GDF-15 in tumor immunotherapy resistance CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Endometrial cancer drug receives breakthrough therapy designation in China HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […] July 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Mage Biologics created to develop oral antibody therapy for ulcerative colitis TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Seven pharma companies form alliance to prepare for future pandemics Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […] July 20, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Biomica announces interim positive results from irritable bowel syndrome program Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Sosei Heptares hails ‘transformational’ acquisition Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […] July 20, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2023 Novel bacterial communication system could help take on antimicrobial resistance A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […] July 19, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2023 Moleculin issues acute myeloid leukemia drug data Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […] July 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email